Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.

T. P. Miller, B. W. Dana, J. K. Weick, S. E. Jones, C. A. Coltman, S. Dahlberg, R. I. Fisher

Research output: Contribution to journalArticlepeer-review

36 Scopus citations

Abstract

The Southwest Oncology Group (SWOG) began testing doxorubicin-containing combination chemotherapy in 1972 using the cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) regimen. Subsequent studies, including 350 patients followed for up to 13.3 years, demonstrated that CHOP was curative in 32% of advanced stage, diffuse large cell lymphomas. More recently, promising results from several institutions suggest that new combinations including methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone (m-BACOD), prednisone, methotrexate, doxorubicin, cyclophosphamide, etoposide, cytarabine, bleomycin, vincristine, methotrexate (ProMACE-CytaBOM), and methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin (MACOP-B) may be superior to CHOP as gauged by complete response (CR) rates. Consequently, the SWOG developed a strategy to compare these regimens directly with CHOP. In 1984 the SWOG began testing these regimens in sequential group-wide phase II trials to confirm therapeutic activity, establish feasibility with regard to toxicity in a cooperative group setting, and gain experience using the complex schedules and dose-modification schemes. Those phase II studies have been completed, and preliminary results indicate that these regimens are active (CR rates, 53% to 65%) and feasible to administer in a cooperative group setting (fatal toxicity, 2% to 6%). We conclude that these three drug regimens can be administered safely in a cooperative group setting, and the CR rates support the current SWOG comparative trial using CHOP as the standard treatment arm.

Original languageEnglish (US)
Pages (from-to)17-22
Number of pages6
JournalSeminars in hematology
Volume25
Issue number2 Suppl 2
StatePublished - Apr 1988

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.'. Together they form a unique fingerprint.

Cite this